<DOC>
	<DOCNO>NCT00111943</DOCNO>
	<brief_summary>The purpose study determine safety acceptability vaginal microbicide HIV uninfected sexually active woman . Study hypothesis : The vaginal microbicide 1 % tenofovir safe well tolerate HIV uninfected woman good general health .</brief_summary>
	<brief_title>Safety Acceptability Vaginal Microbicide</brief_title>
	<detailed_description>While male condom effective prevent sexual transmission HIV , use hamper deeply rooted cultural social barrier . About half HIV infection worldwide occur woman , yet available female-controlled method HIV prevention female condom . Alternative prevention tool , vaginal microbicides , urgently need slow rapid spread heterosexual HIV infection . This study last 24 week , additional 10 week follow-up participant chronic hepatitis B virus ( HBV ) infection . Participants randomly assign one four arm . Arm A participant insert vaginal tenofovir 1 % gel two hour prior vaginal intercourse maximum two daily application . Arm B participant insert vaginal placebo gel two hour prior vaginal intercourse maximum two daily application . Arm C participant insert vaginal tenofovir 1 % gel daily bedtime long period daily rest . Arm D participant insert vaginal placebo gel daily bedtime long period daily rest . A medical menstrual history update , pregnancy test , HIV sexually transmit infection ( STI ) risk reduction counseling , interview ass behavior toward vaginal gel use occur study visit . HIV/STI counsel testing , urinalysis , blood collection occur study entry Week 24 . Pelvic exam colposcopy vaginal swab collection occur study entry Weeks 4 , 12 , 24 . For participant chronic HBV , additional blood collect monitor hepatitis B infection study entry Weeks 12 , 24 , 28 , 32 , 36 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV uninfected Good general health Sexually active Willing use acceptable method contraception , include male latex condom act intercourse Willing undergo studyrelated assessment adhere requirement study Menopausal postmenopausal Hysterectomy Abnormal screen result several gynecologic exam Taking plan take tenofovir , adefovir , medication chronic HBV infection History latex allergy History adverse reaction tenofovir adefovir Use diaphragm spermicide contraception Prior participation study Prior participation vaginal microbicide , spermicide , drug study within 30 day study entry Gynecologic surgical procedure within 90 day study entry Illicit injection drug use within 12 month study entry History vaginal intercourse average two time per day two week prior study screen Any criterion , investigator 's opinion , may interfere study Current pregnancy previous pregnancy within 90 day study entry Breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Anti-Infective Agents , Local</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Vaginal gel</keyword>
	<keyword>Microbicide</keyword>
	<keyword>Vaginal Microbicide</keyword>
	<keyword>PMPA</keyword>
</DOC>